· The proprietary P2 Plasma Enrichment method leverages a novel single-well, single particle-type enrichment method to achieve market-leading performance for unbiased, deep mass spectrometry-based plasma proteomics
· P2 now offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological or population proteomics research· P2 Plasma Enrichment is available as a CRO service via Biognosys’ TrueDiscovery® platform, or as an in-house method for high-performance mass spectrometry end-users via licensing
· With the optional additional combination of TrueDiscovery® unbiased, deep mass spectrometry proteomics workflows with targeted Alamar NULISA affinity-based ultra-high sensitivity proteomics panels, Biognosys now enables the most quantitative and complete access to the human plasma proteome
ZURICH, Switzerland and NEWTON, Mass., May 31 (Bernama-GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, today announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible, superior economics. P2-based plasma proteomics can be used for human or for animal-model proteomics studies and clinical research.
This novel P2 plasma proteomics method achieves a proteome coverage of 7,000 proteins in a previously published five-cancer plasma sample set, demonstrating highest reproducibility, unprecedented enrichment of low abundant proteins, and unparalleled throughput on Bruker timsTOF® HT mass spectrometers. The technical features and performance data will be presented at the American Society of Mass Spectrometry (ASMS) Annual Conference in Anaheim, CA on Monday, June 3rd during Biognosys’ Breakfast Seminar, “Accelerating Drug Discovery and Development with Biognosys’ Next-Generation Proteomics Services,” and on Wednesday, June 5th during the WP 084 poster session.
“With our proprietary P2 Plasma Enrichment method, Biognosys can now significantly enhance the depth and throughput in plasma proteomics beyond what existing methods could achieve,” explains Dr. Oliver Rinner, CEO and founder of Biognosys. “Most importantly, this advancement comes with exceptional reproducibility, which is crucial for quantitative studies. It also provides superior economics and achieves a false discovery rate of less than 1%, that cannot be matched with expensive, high-plex affinity-based methods. Additionally, our optional licensing model now also opens a new avenue for advanced proteomics mass spectrometry end-users to access our cutting-edge methods and software for in-house use.”
Dr. Rohan Thakur, President Bruker LSMS Division, says: “Biognosys' state-of-the-art P2 Plasma method enables profiling of the plasma proteome with rigor, providing deep insights into protein expression, and uniquely leverages the proven robustness of the timsTOF HT. A powerful combination that will provide superior data-completeness with simplicity, both of significant value for large cohort studies.”
No comments:
Post a Comment